Of note, tumors coopt the activities of the purinergic CD39/CD73/adenosine system to shape the immune landscape in the tumor microenvironment at multiple levels (Figure 1): For example, tumor cells and tumor-associated Treg use CD73-dependent adenosine generation to dampen intratumoral immune responses, particularly in hypoxic tumors (229, 230). This evidence concerns the gene NT5E and neoplasm.